We are excited to highlight Dr. Vivek Subbiah as a prominent figure in the field of oncology and early-phase drug development.
Dr. Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute in the USA. Previously, he served as the Executive Director of Oncology Research and an Associate Professor in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center. His extensive expertise lies in translational cancer research, focusing on the design and implementation of biomarker-driven clinical trials.
With a keen interest in antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials, Dr. Subbiah’s work is pivotal in advancing innovative cancer therapies. His contributions aim to enhance treatment options and improve outcomes for patients through cutting-edge research and clinical applications.
Follow Dr. Vivek Subbiah on X/Twitter and LinkedIn to stay updated on his groundbreaking research and insights into early-phase drug development and cancer treatment strategies.
About Dr. Vivek Subbiah
Dr. Vivek Subbiah is a distinguished leader in oncology, renowned for his commitment to advancing cancer therapeutics. As Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, he plays a critical role in pioneering innovative approaches to cancer treatment.
His previous tenure at MD Anderson Cancer Center solidified his reputation as a key player in the field, where he focused on the intricacies of early-phase clinical trials and translational research. Dr. Subbiah’s work not only targets new drug formulations but also emphasizes the importance of biomarker-driven strategies in developing effective therapies.
Stay tuned for more profiles of OncoInfluencers and explore our website to discover other influential voices in the oncology and global health communities.
